Affordable Access

deepdyve-link
Publisher Website

A pharmacokinetic evaluation of oral edivoxetine hydrochloride for the treatment of attention deficit-hyperactivity disorder.

Authors
  • Markowitz, John S
  • Brinda, Bryan J
Type
Published Article
Journal
Expert Opinion on Drug Metabolism & Toxicology
Publisher
Informa UK (Taylor & Francis)
Publication Date
Sep 01, 2014
Volume
10
Issue
9
Pages
1289–1299
Identifiers
DOI: 10.1517/17425255.2014.939955
PMID: 25019201
Source
Medline
Keywords
License
Unknown

Abstract

Available data suggest edivoxetine is safe and well tolerated. Edivoxetine is readily absorbed with metabolism proceeding through the CYP hepatic enzyme pathway, with CYP2D6 and CYP3A4 playing the most prominent roles. The tmax is ∼ 2 h post-dose, and the plasma t1/2 is ∼ 4 - 6 h irrespective of the dose. Pharmacokinetic parameters are not substantially different between children and adults. Edivoxetine may be a promising non-stimulant therapeutic agent. However, at present, there is insufficient data available to permit a thorough analysis of its potential place in ADHD pharmacotherapy, or how its PK and pharmacodynamics may differ in clinically meaningful ways from existing agents.

Report this publication

Statistics

Seen <100 times